Vaccine spurs Pfizer gains

PFIZER INC. $48 is a buy. The prescription drug maker (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 5.6 billion; Market cap: $268.8 billion; Price-to-sales ratio: 4.8; Dividend yield: 3.3%; TSINetwork Rating: Above Average; www.pfizer.com) hit a new all-time high of… Read More

Two buys on the right track for growth

Long-time readers know that we keep you informed of important news about the stocks we cover. That means highlighting developments or strategies that promise to brighten your prospects. Here are two buys that stand out this month:
THERMO FISHER SCIENTIFIC INC. $544.66, is a buy. The… Read More

Dividend Advisor Hotline – Friday, July 30, 2021

PFIZER INC., $42.81, New York symbol PFE, is a top pick for 2021.

The company is one of the world’s largest makers of prescription drugs. Its top-selling brands include Lyrica (epilepsy), Celebrex (arthritis pain), Prevnar (pneumonia) and Enbrel (rheumatoid arthritis).

With the March 2021 payment, Pfizer raised… Read More

Spinoff and activist will benefit Glaxo

Pharmaceutical giant GlaxoSmithKline has stayed in an narrow range of $33 to $48 in the past five years as it struggled with high costs and poor acquisitions.
The company now plans to re energize its growth by spinning off its consumer business as a separate company… Read More

Dividend Advisor Hotline – Friday, July 9, 2021

PFIZER INC., $39.61, New York symbol PFE, is a top pick for 2021.

The company is one of the world’s largest makers of prescription drugs. Its top-selling brands include Lyrica (epilepsy), Celebrex (arthritis pain), Prevnar (pneumonia) and Enbrel (rheumatoid arthritis).

With the March 2021 payment, Pfizer raised… Read More